755P B7H3-targeted tri-specific killer engagers deliver IL-15 to NK cells but not T-cells, and specifically target solid tumors as a pan-tumor antigen strategy mediated through NK cells
Jeffrey S. Miller(Science Museum of Minnesota), Martin Felices(University of Minnesota), F. Cichocki(University of Minnesota Medical Center), Antoun Merino(University of Minnesota Medical Center), Zachary Davis(University of Minnesota), Melissa Khaw(University of Minnesota), G. Phung(University of Minnesota Medical Center), G.I. Berk, H. Hamsher(University of Minnesota Medical Center), Peter K. Howard(University of Minnesota Medical Center), Nicholas A. Zorko(University of Minnesota Medical Center)
Cited by 9
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195